Graphical Abstract Keywords Metabolic dysfunction-associated steatotic liver disease, Glucagon-like peptide-1 receptor agonist, Clinical trial, Treatment, Metabolic dysfunction-associated steatohepatitis, Fibrosis Introduction Nonalcoholic fatty liver disease has been used to describe hepatic steatosis without significant alcohol intake
Adems, aumentan la sensacin de saciedad, reducen el apetito y ayudan a controlar la ingesta calrica, lo que los hace ideales para programas de manejo de peso
Participants were 49.7% male, 77.5% White, 12.6% Black or African American and 35.0% of Hispanic or Latino ethnicity
The summary-level data of Genome-Wide Association Studies (GWASs) used in Mendelian randomization study can be accessed by the FinnGen ( and GTEx ( Abbreviations GLP-1 RAs: Glucagon-like peptide-1 receptor agonists DR: Diabetic retinopathy MR: Mendelian randomization HR: Hazard ratio SMR: Summary-data-based Mendelian randomization OR: Odds ratio CI: Confidence interval CVOTs: Cardiovascular outcome trials ICD-10: International Classification of Diseases, Revision 10 ATC: Anatomical Therapeutic Chemical DDD: Defined daily dose cis-eQTL: Cis-expression quantitative trait loci GWAS: Genome-Wide Association Study CVD: Cardiovascular disease SD: Standard deviation SNP: Single nucleotide polymorphism MAF: Minor allele frequency HEIDI: Heterogeneity in dependent instruments References Shah AR, Gardner TW
